Medtronic acquires Medina Medical to strengthen its neurovascular division

Medtronic acquired Medina Medical, a medical device company developing a device to treat cerebral aneurysms. Medtronic had previously invested and held an ownership stake in Medina Medical, which is based in Menlo Park, Calif.

Medtronic said in a news release that it would pay $150 million in cash for Medina and make additional payments if Medina meets certain milestones, which were not detailed.

Medina’s embolization device is an intrasaccular 3D mesh implant that fills the inside of a brain aneurysm. It is not FDA-approved, but it is available in Europe.

Medina will be part of Medtronic’s neurovascular division within its restorative therapies group. Medtronic said the deal strengthens its stroke portfolio.

In the U.S., approximately six million people have an aneurysm, although most are undiagnosed. Each year, more than 35,000 patients are treated endovascularly and 21,000 are treated surgically, according to Medtronic.

The deal is the latest in a series of acquisitions for Medtronic. This summer, Medtronic has acquired a few small companies, including CardioInsightAptus EndosystemsRF Surgical Systems and Twelve.

Tim Casey,

Executive Editor

Tim Casey joined TriMed Media Group in 2015 as Executive Editor. For the previous four years, he worked as an editor and writer for HMP Communications, primarily focused on covering managed care issues and reporting from medical and health care conferences. He was also a staff reporter at the Sacramento Bee for more than four years covering professional, college and high school sports. He earned his undergraduate degree in psychology from the University of Notre Dame and his MBA degree from Georgetown University.

Around the web

Several key trends were evident at the Radiological Society of North America 2024 meeting, including new CT and MR technology and evolving adoption of artificial intelligence.

Ron Blankstein, MD, professor of radiology, Harvard Medical School, explains the use of artificial intelligence to detect heart disease in non-cardiac CT exams.

Eleven medical societies have signed on to a consensus statement aimed at standardizing imaging for suspected cardiovascular infections.